Literature DB >> 7707313

Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogues of thiazole-4-carboxamide adenine dinucleotide.

A Zatorski1, B M Goldstein, T D Colby, J P Jones, K W Pankiewicz.   

Abstract

Three analogues of thiazole-4-carboxamide adenine dinucleotide (TAD) (1-3) containing a fluorine atom at the C2' of the adenine nucleoside (in the ribo and arabino configuration) and at the C3' (in the ribo configuration) were synthesized in high yield from the corresponding 5'-monophosphates of 2'-deoxy-2'-fluoroadenosine (9), 9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-adenine (17), and 3'-deoxy-3'-fluoroadenosine (14), respectively. Pure 2',3'-O-isopropylidene-tiazofurin 5'-phosphorimidazolide (8) was obtained by phosphorylation of the protected tiazofurin followed by treatment with carbonyldiimidazole and HPLC purification. Reaction of 8 with 9 in DMF-d7 (monitored by 1H and 31P NMR) afforded the desired dinucleotide 12, which after deisopropylidenation gave 1 in 82% yield. Small amounts of symmetrical dinucleotides AppA (10, 7.2%) and TRppTR (11, 8.0%) were also isolated during HPLC purification of the major product 12. In a similar manner, compounds 2 and 3 were obtained by coupling of 8 with 14 and 17 in 80% and 76% yield, respectively. All newly prepared fluoro-substituted compounds as well as beta-CF2-TAD, earlier synthesized by us, showed good inhibitory activity against inosine monophosphate dehydrogenase type II, the isozyme which is predominant in neoplastic cells. Binding of 1 (Kis = 0.5 microM), 2 (Kis = 0.7 microM), and 3 (Kis = 2.9 microM) was comparable to that of TAD (Ki = 0.2 microM). The difluoromethylene bisphosphonate analogue, beta-CF2-TAD (Ki = 0.17 microM), was found to be equally effective as the best cofactor-type inhibitor, beta-CH2-TAD (Ki = 0.11 microM). Interestingly, the level of inhibition of horse liver alcohol dehydrogenase by these compounds was found to be much lower (0.1 mM for 1 and 2 and no inhibition up to 10 mM for 3). These findings show that inhibition of tumor-induced inosine monophosphate dehydrogenase type II is selective and may be of therapeutic interest.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707313     DOI: 10.1021/jm00007a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold.

Authors:  Shay Eliahu; Haim M Barr; Jean Camden; Gary A Weisman; Bilha Fischer
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

2.  Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.

Authors:  Hak Sung Kim; R Gnana Ravi; Victor E Marquez; Savitri Maddileti; Anna-Karin Wihlborg; David Erlinge; Malin Malmsjö; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

3.  Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.

Authors:  Shir Yelovitch; Haim M Barr; Jean Camden; Gary A Weisman; Ela Shai; David Varon; Bilha Fischer
Journal:  J Med Chem       Date:  2012-08-20       Impact factor: 7.446

Review 4.  Beyond Triphosphates: Reagents and Methods for Chemical Oligophosphorylation.

Authors:  Scott M Shepard; Henning J Jessen; Christopher C Cummins
Journal:  J Am Chem Soc       Date:  2022-04-26       Impact factor: 16.383

5.  Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking.

Authors:  H S Kim; D Barak; T K Harden; J L Boyer; K A Jacobson
Journal:  J Med Chem       Date:  2001-09-13       Impact factor: 8.039

Review 6.  Synthetic Strategies for Dinucleotides Synthesis.

Authors:  Lucie Appy; Crystalle Chardet; Suzanne Peyrottes; Béatrice Roy
Journal:  Molecules       Date:  2019-11-27       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.